FDA
-
-
-
-
-
-
-
Inventiva (IVA) secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the US
-
-
-
-
-
-
-
Inventiva reports its 2022 first-half financial results and provides a corporate update
-
-
-
-
-
-
-
Inventiva announces the schedule of publication and presentation of its 2021 Full-Year Financial Results
-
-
-
-
-
-
-
Inventiva reports 2021 Third Quarter Financial Information
-
-
-
-
-
-
-
Inventiva (IVA) Granted FDA's Fast Track Designation of lanifibranorin NASH Encompasses the Treatment of NASH with Compensated Cirrhosis
-
-
-
-
-
-
-
Inventiva (IVA) announces implementation of At-The-Market program for Up to $100M
-
-
-
-
-
-
-
Inventiva announces design of Phase III clinical trial with lanifibranor in NASH
-
251,687 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All